Where Does Wall Street Think Meridian Bioscience, Inc. (VIVO) Stock Will Go?

Monday, November 29, 2021 03:39 PM | InvestorsObserver Analysts

Mentioned in this article

Where Does Wall Street Think Meridian Bioscience, Inc. (VIVO) Stock Will Go?

InvestorsObserver is giving Meridian Bioscience, Inc. (VIVO) an Analyst Rating Rank of 74, meaning VIVO is ranked higher by analysts than 74% of stocks. The average price target for VIVO is $28 and analyst’s rate the stock as a Strong Buy.

Wall Street analysts are rating VIVO a Strong Buy today. Find out what this means to you and get the rest of the rankings on VIVO!

See Full VIVO Report

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Meridian Bioscience, Inc. Stock Today?

Meridian Bioscience, Inc. (VIVO) stock is lower by -1.18% while the S&P 500 is up 1.55% as of 3:39 PM on Monday, Nov 29. VIVO is down -$0.24 from the previous closing price of $20.35 on volume of 277,276 shares. Over the past year the S&P 500 has gained 28.83% while VIVO is up 6.40%. VIVO earned $1.62 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 12.39. Click Here to get the full Stock Report for Meridian Bioscience, Inc. stock.